» Articles » PMID: 24698233

Female Gender and Contrast-induced Nephropathy in Primary Percutaneous Intervention for ST-segment Elevation Myocardial Infarction

Overview
Journal Int J Cardiol
Publisher Elsevier
Date 2014 Apr 5
PMID 24698233
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patients undergoing primary percutaneous coronary intervention (PCI) are at high risk for contrast-induced nephropathy (CIN), a complication that has been demonstrated to negatively affect outcomes. It has been suggested that, when compared to males, female patients present higher incidence of CIN and higher mortality after primary PCI. However, the specific role of gender in this setting remains ill-defined given its complex interplay with several co-morbidities and clinical characteristics. We investigated the relationship of patients' variables, including gender, with CIN and mortality after primary PCI.

Methods: In a single center study in 323 consecutive patients undergoing primary PCI, the development of CIN and mortality during an 18-month median follow-up period was assessed. CIN was defined as an increase in serum creatinine (≥25% or ≥0.5 mg/dl) from baseline occurring at any time during the first 3 post-procedural days.

Results: CIN occurred in 23 female and 26 male patients (25.0% vs 11.2%, p=0.003), while cumulative mortality was 10.6%. Women presented unfavorable basal characteristics and underwent myocardial reperfusion less quickly. At multivariable analysis, reduced left ventricular ejection fraction (LVEF) (odds ratio [OR] 7.32 95% confidence interval [CI]: 2.60-21, p<0.001) and female gender (OR 2.49 95%CI 1.22-5.07, p=0.01) predicted CIN, whereas the occurrence of CIN (hazard ratio [HR] 3.65 95%CI 1.55-8.59, p=0.003) and a Mehran risk score (MRS)≥6 (HR 1.76 95%CI 1.13-2.74, p=0.01) independently predicted long-term mortality.

Conclusions: After primary PCI, female gender and LVEF are associated with an increased risk of CIN, whereas MRS and development of CIN predict long-term mortality.

Citing Articles

Gender Differences in Pharmacokinetics: A Perspective on Contrast Agents.

Courchesne M, Manrique G, Bernier L, Moussa L, Cresson J, Gutzeit A ACS Pharmacol Transl Sci. 2024; 7(1):8-17.

PMID: 38230293 PMC: 10789139. DOI: 10.1021/acsptsci.3c00116.


Risk Factors Associated With Contrast-Induced Nephropathy after Primary Percutaneous Coronary Intervention.

Kumar D, Liaquat H, Sial J, Saghir T, Kumari R, Kumar H Cureus. 2020; 12(8):e9721.

PMID: 32944440 PMC: 7489321. DOI: 10.7759/cureus.9721.


Impact of renal function on patients with acute coronary syndromes: 15,593 patient-years study.

Kuzma L, Malyszko J, Kurasz A, Niwinska M, Zalewska-Adamiec M, Bachorzewska-Gajewska H Ren Fail. 2020; 42(1):881-889.

PMID: 32862755 PMC: 7472470. DOI: 10.1080/0886022X.2020.1810069.


CHA2DS2-VASc score as a novel predictor for contrast-induced nephropathy after percutaneous coronary intervention in acute coronary syndrome.

Chaudhary A, Pathak V, Kunal S, Shukla S, Pathak P Indian Heart J. 2019; 71(4):303-308.

PMID: 31779857 PMC: 6890954. DOI: 10.1016/j.ihj.2019.09.005.


CHA2DS2-VASC Score Predicts Risk of Contrast-Induced Nephropathy in Non-ST Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Interventions.

Baydar O, Kilic A Kidney Dis (Basel). 2019; 5(4):266-271.

PMID: 31768384 PMC: 6873045. DOI: 10.1159/000501036.